Financial Performance - The company's operating revenue for 2022 was ¥666,562,814.54, a decrease of 32.29% compared to ¥984,448,664.58 in 2021[19]. - The net profit attributable to shareholders for 2022 was ¥140,965,003.50, down 35.94% from ¥220,048,412.44 in 2021[19]. - The net profit after deducting non-recurring gains and losses was ¥129,512,124.15, a decline of 38.39% from ¥210,221,265.88 in 2021[19]. - The total operating revenue for 2022 was ¥666,562,814.54, representing a decrease of 32.29% compared to ¥984,448,664.58 in 2021[53]. - The gross profit margin for the other daily chemical products manufacturing industry was 30.03%, down 2.16% from the previous year[56]. - The company reported a significant decrease in accounts receivable, which fell to ¥139,007,502.17, a reduction of 1.16% from the previous year[77]. - The company reported a total revenue of 1.5 billion CNY for the fiscal year 2022, representing a year-over-year increase of 15%[150]. - The gross margin improved to 45%, up from 40% in the previous year, due to cost optimization strategies[150]. Dividend and Profit Distribution - The company reported a profit distribution plan, proposing a cash dividend of 5 RMB per 10 shares, based on a total of 81,209,818 shares[3]. - The company plans to distribute a cash dividend of 5.00 CNY per 10 shares, totaling 40,604,909.00 CNY, which represents 100% of the distributable profit[171]. - The cash dividend distribution aligns with the company's articles of association and dividend management measures[171]. Market and Product Development - The company is focused on expanding its market presence and developing new products, although specific figures and timelines were not disclosed in the provided content[3]. - The global retail market size for wet wipes reached $17 billion in 2022, with expectations to grow to $21.8 billion by 2027[31]. - The Chinese wet wipes market reached a size of 12.6 billion yuan in 2022, projected to grow to 20.7 billion yuan by 2027[32]. - The company is expanding its product line into personal care products, with a focus on establishing a technology R&D center in Shanghai[40]. - The company launched a 3,000 tons/year personal care product project in 2022, expanding its cosmetics business beyond facial masks[50]. - New product development efforts have led to the introduction of three innovative products in the biotechnology sector, expected to contribute an additional 200 million CNY in revenue[122]. - The company is planning to expand its market presence in Southeast Asia, targeting a 15% market share within the next two years[122]. Research and Development - The company has developed a "zero preservative" and "pure water" formula series for baby wipes, emphasizing minimal additives[34]. - The company has 6 utility model patents and 43 design patents in the wet wipes technology field, ensuring a strong R&D advantage[40]. - The company completed the development of new plant-based moisturizing skincare wipes, enhancing product competitiveness and formulation options[65]. - The company is focusing on expanding its product line to include more environmentally friendly options, responding to consumer demand for "zero preservatives"[66]. - The company has invested 100 million RMB in R&D for new technologies aimed at improving product efficiency[150]. - The number of R&D personnel decreased by 13.33% from 90 in 2021 to 78 in 2022, while the proportion of R&D personnel increased from 11.28% to 12.58%[69]. Risk Management - The report includes a detailed section on future risks and countermeasures, highlighting the company's proactive approach to potential challenges[3]. - The company faces risks related to technology research and development, including potential setbacks in achieving key technological breakthroughs, which could impact market share and sales orders[108]. - Fluctuations in raw material prices, particularly for non-woven fabrics and packaging materials, pose a significant risk to the company's profitability, as direct materials constitute a high proportion of the main business costs[109]. - The company faces exchange rate fluctuation risks due to export trade primarily settled in USD, which may impact financial performance[113]. - The company has implemented a comprehensive risk assessment system to identify and manage internal and external risks, ensuring operational safety[188]. Corporate Governance - The company held 11 board meetings during the reporting period, adhering strictly to relevant laws and regulations[127]. - The board consists of 9 directors, including 3 independent directors, complying with legal and regulatory requirements[128]. - The company maintains complete independence in assets, personnel, finance, organization, and business from its controlling shareholders[129]. - The company has established a governance structure combining the shareholders' meeting, board of directors, supervisory board, and management team to ensure effective decision-making and supervision[180]. - The company is committed to maintaining transparency and accountability in its financial reporting and corporate governance practices[142]. Financial Management - The company raised a total of RMB 1,162,721,769.66 from its initial public offering, with a net amount of RMB 1,031,831,424.91 after deducting issuance costs[91]. - The company has approved the use of RMB 190 million of over-raised funds to permanently supplement working capital, accounting for 28.96% of the total over-raised funds[91]. - The company has established a budget management system that clearly defines principles, responsibilities, and procedures to support strategic development[194]. - The company has a strict external guarantee management system in place, with defined approval authority and procedures to mitigate potential risks associated with guarantees[198]. Employee Management - The company has implemented a restricted stock incentive plan for 2022, linking employee compensation to company performance and individual growth[168]. - The total remuneration for directors, supervisors, and senior management in 2022 amounted to 4.9039 million yuan[156]. - The company is committed to building a learning organization, enhancing employee training and skill development through various programs[169]. - The company has established a comprehensive employee training management system to ensure continuous skill enhancement[169].

Financial Performance - The company's revenue for Q1 2023 was ¥127,803,768.87, a decrease of 29.24% compared to ¥180,610,587.09 in the same period last year[5] - Net profit attributable to shareholders was ¥37,270,675.22, down 21.45% from ¥47,447,960.74 year-on-year[5] - Basic earnings per share decreased by 20.69% to ¥0.46 from ¥0.58 in the same period last year[5] - Total operating revenue for Q1 2023 was ¥127,803,768.87, a decrease of 29.3% compared to ¥180,610,587.09 in Q1 2022[19] - Net profit for Q1 2023 was ¥37,262,970.59, representing a decline of 21.5% from ¥47,447,960.74 in Q1 2022[20] - Earnings per share for Q1 2023 was ¥0.46, down from ¥0.58 in the same period last year[20] Cash Flow - The net cash flow from operating activities was ¥20,696,967.09, a significant decline of 84.60% from ¥134,352,344.73 in the previous year[5] - Total cash inflow from operating activities was ¥160,217,296.07, compared to ¥331,014,121.40 in the previous year, indicating a decrease of about 51.7%[23] - The cash outflow from operating activities was ¥139,520,328.98, down from ¥196,661,776.67, representing a reduction of approximately 29.1%[23] - The net cash flow from investing activities was -¥245,469,814.02, compared to -¥258,852,991.50 in Q1 2022, showing a slight improvement[23] - The net cash flow from financing activities was ¥960,000.00, unchanged from the previous year[24] - The company reported a cash decrease of ¥223,897,592.82 during the quarter, compared to a decrease of ¥125,467,510.94 in the same period last year[24] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,059,369,867.12, a slight decrease of 0.36% from ¥2,066,863,492.46 at the end of the previous year[5] - Total liabilities decreased to ¥238,626,140.98 from ¥287,729,528.80, reflecting a reduction of 17.1%[19] - Total equity increased to ¥1,820,743,726.14, up from ¥1,779,133,963.66, indicating a growth of 2.3%[19] - Cash and cash equivalents decreased to ¥775,574,364.16 from ¥1,004,571,421.92 at the beginning of the year, a decline of approximately 22.7%[16] - Total assets decreased slightly to ¥2,059,369,867.12 from ¥2,066,863,492.46, a decline of about 0.4%[16] Shareholder Information - Total number of common shareholders at the end of the reporting period is 9,972[12] - The largest shareholder, Cai Yingchuan, holds 52.88% of shares, totaling 42,946,052 shares[12] - The company has a significant shareholder structure with the top 10 shareholders holding a combined total of 80.33% of shares[12] Investment Activities - The company reported a 48.13% increase in trading financial assets, amounting to ¥445,303,748.10, due to idle funds being used to purchase financial products[9] - The company recorded a 136.00% increase in cash paid for investments, totaling ¥590,000,000.00, attributed to the purchase of financial products and large-denomination certificates of deposit[10] - The company is actively managing its investments, with debt investments increasing to ¥382,749,792.18 from ¥280,516,906.74, a rise of about 36.5%[16] - The company reported an investment income of ¥4,500,068.75 for Q1 2023, with no comparable figure from the previous year[19] Operational Performance - The company experienced a 29.24% decline in operating income primarily due to reduced sales of disinfectant wet wipes[9] - Cash received from sales decreased by 48.15% to ¥153,842,996.08 compared to ¥296,695,480.37 in the previous year[10] - Total operating costs decreased to ¥93,994,590.15, down 27.1% from ¥129,144,546.40 in the previous year[19] - Research and development expenses for Q1 2023 were ¥5,090,366.20, a slight decrease from ¥6,045,982.83 in Q1 2022[19] Other Financial Metrics - The company’s weighted average return on equity decreased to 2.07% from 2.76% year-on-year[5] - Deferred income tax liabilities increased to ¥17,394,921.76 from ¥14,738,979.68, marking a rise of 17.9%[19] - Financial expenses improved, showing a net income of -¥4,436,903.13 compared to -¥5,433,757.22 in the previous year[19] Miscellaneous - The company did not conduct an audit for the Q1 report[25] - The company experienced a negative impact of ¥84,745.89 from exchange rate fluctuations on cash and cash equivalents[24]

证券代码：301108 证券简称：洁雅股份 公告编号：2023-026 铜陵洁雅生物科技股份有限公司 关于举行 2022 年度网上业绩说明会的公告 为便于广大投资者更深入、全面地了解公司情况，公司定于 2023 年 4 月 28 日（星期五）15:00-17:00 在全景网举办 2022 年度网上业绩说明会，本次业绩说 明会将采用网络远程的方式举行，投资者可登陆全景网"投资者关系互动平台" （http://ir.p5w.net）参与本次年度业绩说明会。 出席本次业绩说明会的人员有：公司董事长兼总经理蔡英传先生、董事兼财 务总监杨凡龙先生、独立董事何文龙先生、副总经理兼董事会秘书胡能华先生、 保荐代表人章付才先生。 为充分尊重投资者、提升交流的针对性，现就公司 2022 年度业绩说明会提 前向投资者公开征集问题，广泛听取投资者的意见和建议。投资者可于 2023 年 4 月 26 日（星期三）前访问 http://ir.p5w.net/zj/进入问题征集专题页面或将您关心 或关注的问题通过电子邮件的形式发送至公司邮箱 zqb@babywipes.com.cn。公司 将在 2022 年度业绩说明会上，对投资者普遍关 ...